Thermo Fisher sells lab division to PE firm for $480M; Dental laser company Biolase raises $12M;

@FierceMedDev: Profit stumble pushes Philips to focus on healthcare. Article | Follow @FierceMedDev

@StacyALawrence: Miss Idaho wears insulin pump in swimsuit competition. Item | Follow @StacyALawrence

@VarunSaxena2: ICYMI yesterday: FDA approves expandable implant for spinal fusion surgery. News | Follow @VarunSaxena2

@MichaelGFierce: RT @EmilyMFierce: Which 15 disease areas get the most funding from NIH? Report | Follow @MichaelGFierce

@EmilyWFierce: Auditory brainstem implant provides alternative to cochlear device, offers profoundly deaf children a chance to hear. More from the Los Angeles Times | Follow @EmilyWFierce

> Thermo Fisher Scientific ($TMO) sold its Cole-Parmer laboratory division to private equity firm GTCR for $480 million. Story

> Dental laser company Biolase to raise $12 million in a private placement with investors including Oracle Partners and Birchview Capital. Release

> USGI Medical garnered a $9 million line of credit from GE Capital to help support its pivotal trial for its endospopic obesity device. Release

Biotech News

@FierceBiotech: $ZIOP, $XON tackle CAR-T in expanded partnership. More | Follow @FierceBiotech

@JohnCFierce: Biosimilars set to boom as new patent cliff on biologic superstars looms. Article | Follow @JohnCFierce

@DamianFierce: "It's like surfing. If you aren't in the water you'll never catch that monster wave." -- CEO on going public. More | Follow @DamianFierce

@EmilyMFierce: Which 15 disease areas get the most funding from NIH? List | Follow @EmilyMFierce

> AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners. Story

> With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia. Article

> Sage takes to the FDA fast track with its lead rare disease drug. News

> Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic. Report

Pharma News

@FiercePharma: Top-read on FP Monday: Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong. Article | Follow @FiercePharma

@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Story | Follow @TracyStaton

@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. More from FierceAnimalHealth | Follow @EricPFierce

@CarlyHFierce: Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Report | Follow @CarlyHFierce

> News flash for biopharma bosses: More than half your employees want to leave. Story

> Cost-conscious payers are eyeing higher prices on diabetes drugs. Report

> Do testosterone meds boost heart attack risks? FDA asks advisory panels to weigh the data. Article

> Touting a Q2 beat and strong Opsumit launch, Actelion CEO dismisses takeover chatter. More

Biotech Research News

> Top 15 NIH-funded disease areas. Report

> Simulated human heart aims to screen drugs for adverse effects. More

> First U.S.-acquired chikungunya case detected. Item

> Simulated human heart aims to screen drugs for adverse effects. Article

> Enzyme may provide new target for Alzheimer's disease. Story

Pharma Manufacturing News

> FedEx to fight charges it was key link in supply chain for illegal drugs. News

> FDA again warns that Texas compounder's products may not be sterile. Item

> GSK, J&J push for genetic engineering of opium. More

> American Health recalls epilepsy drug and ibuprofen over possible tablet switch. Story

> Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.